Chris Frankenfield

Christopher Frankenfield is a seasoned legal and operational executive with extensive experience in the biotechnology and pharmaceutical sectors. Currently serving as the Chief Operating Officer, Chief Legal and Administrative Officer, and Senior Vice President and General Counsel at Xilio Therapeutics, Inc. since March 2021, Christopher previously held multiple roles at Blueprint Medicines from August 2015 to March 2021, including Vice President of Corporate Legal Affairs. Prior to that, Christopher worked as a Senior Associate at WilmerHale and gained early experience through internships and summer associate positions at various firms, including Kilpatrick Stockton and PricewaterhouseCoopers. Christopher holds a JD from the University of Virginia School of Law and a BA in Economics and Finance from William & Mary.